Welcome
Support Centre
19 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin beta
ISRCTN ISRCTN66395033
ClinicalTrials.gov identifier
Public title The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin beta
Scientific title
Acronym N/A
Serial number at source ESA-2
Study hypothesis That treating patients with anaemia in diabetic nephropathy to a higher haemoglobin target range decreases rate of decline of renal function, requirement for dialysis, doubling of creatinine and death.
Ethics approval Applied for to the East London and the City Health Authority Reserach Ethics Committee One - expecting to go to Ethics meeting in early November 2006.
Study design Randomised, controlled, open trial
Countries of recruitment United Kingdom
Disease/condition/study domain Anaemia in diabetic nephropathy
Participants - inclusion criteria 1. Male and female patients with diabetic nephropathy and chronic kidney disease III and IV
2. Age more than 18 years and less than 80 years
3. Haemoglobin less than 11.5 g/dl
Participants - exclusion criteria 1. Current treatment with an erythropoiesis-stimulating agent (ESA)
2. Uncontrolled hypertension
3. Congestive cardiac failure
4. History of seizures
5. History of thrombotic episodes
6. Pregnancy
7. Lactation
8. Presence of systemic disease, infection or inflammatory conditions
9. Hepatic insufficiency
10. Active hepatitis
11. Uncontrolled hypothyroidism
12. Chronic alcoholism
13. Known hypersensitivity to the active substance in the cartridge or benzoic acid
14. Known sensitivity to epoetin beta
Anticipated start date 01/12/2006
Anticipated end date 30/11/2009
Status of trial Ongoing
Patient information material
Target number of participants 160
Interventions All patients should be iron replete (i.e. ferritin 0.1 or Tsats 0.2%) before randomisation. Participants will be given intravenous (IV) iron to replete iron stores if required before randomisation.

Participants will be randomised to two target ranges of haemoglobin on a 1:1 basis. Target ranges:
1. Hb 10.5 - 12 g/dl
2. Hb 12.1 - 13.5 g/dl

Participants will be treated with Epoetin Beta subcutaneously, if required, to maintain their haemoglobin within the target group. This will be a starting dose of 50 units/kg/week given once a week. Dose will be titrated on a monthly basis to start with, and then modified according to response (total dose 720 units/kg/week). Participants will be treated for three years.
Primary outcome measure(s) 1. Rate of decline of renal function as determined by estimated glomerular filtration rate (GFR)
2. Composite end-point of:
2.1. Doubling of creatinine
2.2. Reaching end-stage renal failure
2.3. Death
Secondary outcome measure(s) 1. Change in left ventricular hypertrophy as measured on echocardiogram
2. Change in intimal and medial wall thickness as determined by intimal thickness and flow dependant vasodilation as determined by ultrasound
3. Change in functional quality of life scores
4. Change in markers of endothelial dysfunction
5. Change of markers of tubular damage in the urine
Sources of funding Salary of research doctor funded through the hospital Research and Develpment Department by Roche Pharmaceuticals ( ML20597) (UK)
Trial website
Publications
Contact name Prof  Magdi  Yaqoob
  Address Department of Kidney and Tranpslant Medicine
West Wing, Basement
Royal London Hospital
Whitechapel
  City/town London
  Zip/Postcode E1 1BB
  Country United Kingdom
Sponsor Barts and the London NHS Trust (UK)
  Address Research and Development Office
3rd Floor Rutland House
42-46 New Road
Whitechapel
  City/town London
  Zip/Postcode E1 2AX
  Country United Kingdom
  Sponsor website: http://www.bartsandthelondon.org.uk/
Date applied 17/10/2006
Last edited 02/09/2008
Date ISRCTN assigned 04/12/2006
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central